Abstract
Cancer cells are known to express cell surface molecules such as specific antigens or cytokine receptors, e.g., EGFR, Fas / CD95, gp100, HER-2 / neu, IL-13Rα2, and MAGE. Among them, interleukin-13 receptor (IL-13R) a2 chain is expressed on certain types of cancer cells including glioblastoma, AIDS Kaposis sarcoma, and head and neck cancer. This protein is one of the receptor components for IL-13, a Th2 cell-derived pleiotropic immune regulatory cytokine. IL- 13Rα2 chain on these cancer cells can be targeted with a receptor-directed cytotoxin termed IL13-PE to induce specific cancer cell killing, however, this molecule does not mediate cytotoxicity to cells that do not express or express low levels of IL-13Rα2. In order to achieve a broad therapeutic window for IL13-PE, plasmid-mediated gene transfer of IL-13Rα2 in cancer cells was employed in vitro and in vivo. Cancer cells transfected with IL-13Rα2 demonstrated increased binding to IL-13 and sensitivity to IL13-PE in vitro. In vivo intratumoral gene transfer of IL-13Rα2 profoundly enhanced the antitumor activity of IL13-PE, providing complete elimination of established tumor in some xenografts. In this review article, current findings from IL-13Rα2 gene transfer in a variety of human cancer models in nude mice are summarized. In addition, safety issues and possible future directions utilizing this therapeutic approach are discussed.
Keywords: cancer gene therapy, interleukin-13, cytokine receptor, immunotherapy, tumor vaccine, immunotoxin
Current Gene Therapy
Title: Cancer Gene Therapy Utilizing Interleukin-13 Receptor α2 Chain
Volume: 5 Issue: 2
Author(s): Koji Kawakami
Affiliation:
Keywords: cancer gene therapy, interleukin-13, cytokine receptor, immunotherapy, tumor vaccine, immunotoxin
Abstract: Cancer cells are known to express cell surface molecules such as specific antigens or cytokine receptors, e.g., EGFR, Fas / CD95, gp100, HER-2 / neu, IL-13Rα2, and MAGE. Among them, interleukin-13 receptor (IL-13R) a2 chain is expressed on certain types of cancer cells including glioblastoma, AIDS Kaposis sarcoma, and head and neck cancer. This protein is one of the receptor components for IL-13, a Th2 cell-derived pleiotropic immune regulatory cytokine. IL- 13Rα2 chain on these cancer cells can be targeted with a receptor-directed cytotoxin termed IL13-PE to induce specific cancer cell killing, however, this molecule does not mediate cytotoxicity to cells that do not express or express low levels of IL-13Rα2. In order to achieve a broad therapeutic window for IL13-PE, plasmid-mediated gene transfer of IL-13Rα2 in cancer cells was employed in vitro and in vivo. Cancer cells transfected with IL-13Rα2 demonstrated increased binding to IL-13 and sensitivity to IL13-PE in vitro. In vivo intratumoral gene transfer of IL-13Rα2 profoundly enhanced the antitumor activity of IL13-PE, providing complete elimination of established tumor in some xenografts. In this review article, current findings from IL-13Rα2 gene transfer in a variety of human cancer models in nude mice are summarized. In addition, safety issues and possible future directions utilizing this therapeutic approach are discussed.
Export Options
About this article
Cite this article as:
Kawakami Koji, Cancer Gene Therapy Utilizing Interleukin-13 Receptor α2 Chain, Current Gene Therapy 2005; 5 (2) . https://dx.doi.org/10.2174/1566523053544227
DOI https://dx.doi.org/10.2174/1566523053544227 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Development of 3-substituted Indolin-2-one Derivatives as Kinase
Inhibitors for Cancer Therapy
Current Medicinal Chemistry Astatine Radiopharmaceuticals: Prospects and Problems
Current Radiopharmaceuticals Crosstalk Between Epidermal Growth Factor Receptor- and Insulin-Like Growth Factor-1 Receptor Signaling: Implications for Cancer Therapy
Current Cancer Drug Targets Performance Improvement of Gene Selection Methods using Outlier Modification Rule
Current Bioinformatics A Critical Review of Second-Generation Anti-EGFR Monoclonal Antibodies in Metastatic Colorectal Cancer
Current Drug Targets Monoclonal Antibody “Gold Rush”
Current Medicinal Chemistry MiRNA, a New Treatment Strategy for Pulmonary Fibrosis
Current Drug Targets Platinum-Based Agents for Individualized Cancer Treatment
Current Molecular Medicine Recent Development of Copolymeric Nano-Drug Delivery System for Paclitaxel
Anti-Cancer Agents in Medicinal Chemistry Inhibitors of the Immunoproteasome: Current Status and Future Directions
Current Pharmaceutical Design EGFR-Targeting Monoclonal Antibodies in Head and Neck Cancer
Current Cancer Drug Targets Rational Combination of Targeted Therapies As A Strategy to Overcome The Mechanisms of Resistance to Inhibitors of EGFR Signaling
Current Pharmaceutical Design Targeting Microtubules to Inhibit Angiogenesis and Disrupt Tumour Vasculature:Implications for Cancer Treatment
Current Cancer Drug Targets Patents Related to Cancer Stem Cell Research
Recent Patents on DNA & Gene Sequences Radiofluorinated Carbohydrates for Positron Emission Tomography
Current Topics in Medicinal Chemistry The Potential of Natural Products as Effective Treatments for Allergic Inflammation: Implications for Allergic Rhinitis
Current Topics in Medicinal Chemistry Inhibition of PI3K/Akt Signaling: An Emerging Paradigm for Targeted Cancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents Translational Research in Oncology: The Need of Additional In Vitro Preclinical Testing Methods for New Drugs
Current Pharmaceutical Design Opportunities and Challenges in Nano-structure Mediated Drug Delivery: Where Do We Stand?
Current Nanomedicine Targeted Gene Therapy for Ovarian Cancer
Current Gene Therapy